Anyone know more about this? sounds promising?
A pathbreaking flu drug is a huge step closer to human trials.
We’ve been on the case for over a year: Back then, there were already data demonstrating the treatment’s vast superiority to Tamiflu, the only flu drug on the market.
“The drug bases its technology on nano-sized polymer ‘decoys’ to induce viruses to harmlessly discharge their genetic material outside of a cell,” Ray and Stephen explain. “Its nano constructs aren’t designed to interact with human biology. Rather, they are designed to interact with viruses directly. This means the likelihood of off-target effects should be lower than with a traditional drug.”
Now come results from toxicology studies: “The compound produces no overt safety and toxicology effects, even at maximum dose levels. This includes an analysis of major organs such as the liver, kidneys and lungs.”
That’s critical as the company behind the compound prepares to submit its Investigational New Drug (IND) application to the FDA; evidence of safety must first be presented before human trials can start.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.